The short answer
5-HTP warrants review before use with fentanyl because of a possible serotonin-related interaction. There is no established safe supplement dose or protective spacing interval for this exact pair.
What this answer covers
Oral L-5-hydroxytryptophan supplements, not routine protein foods.
- Supplement or preparation
- L-5-HTP
- Medication ingredient
- fentanyl
Why review is appropriate
The supplement guidance raises concern with medicines that affect serotonin, and fentanyl labeling warns about serotonin syndrome with serotonergic co-medication. This supports a precaution without proving the exact combination causes toxicity.
Human observations put the risk in context
In one hospital chart review, only a small minority of patients receiving fentanyl and serotonergic medicines met serotonin-toxicity criteria. The study could miss cases and did not establish a risk rate for this supplement.
Laboratory findings do not settle the clinical question
Fentanyl did not inhibit serotonin or noradrenaline transporters in one laboratory study. This differs from some other analgesics, but does not cancel clinical reports or the fentanyl label warning. No supplement combination was tested.
Do not substitute a timing rule for review
Tell the prescriber or anesthesia team about the product and other medicines. Short dose separation has not been shown to prevent this concern, and the label’s MAOI precautions are not a universal herbal washout rule. Agitation with fever, tremor, rigidity or confusion requires urgent assessment.
Evidence and practical considerations
Side effects & toxicity
Conditional serotonergic review precaution from exact fentanyl labels and supplement-specific guidance; low observed cohort frequency and transporter-null finding retained. No exact-pair incidence, protective gap or universal prohibition.
- Exact scope
- Oral L-5-hydroxytryptophan supplements, not routine protein foods. with Fentanyl4337 IN; human IV/IM citrate or transdermal product with opioid-tolerance and route boundaries.
- Medication form and route
- intravenous medication; intramuscular medication; transdermal medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed fentanyl
Opioid respiratory depression/CNS-depressant warnings and serotonin-syndrome precautions with serotonergic drugs.
How this applies: Exact fentanyl RxCUI 4337 IN, with stated salt/formulation/route bridge.
Not transdermal or transmucosal dosing; no supplement-specific event rate.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed fentanyl
CNS-depressant and serotonergic interaction warnings; heat and formulation-specific exposure risks.
How this applies: Exact fentanyl RxCUI 4337 IN, with stated salt/formulation/route bridge.
Not appropriate for opioid-naive patients or acute postoperative pain; surgical IV studies cannot define patch co-use safety.
Source 3: regulatory supplement monograph
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adult oral 5-HTP users
Consult before serotonergic co-use; possible drowsiness. Dextromethorphan-containing cough medicine specifically named among serotonergic products.
How this applies: Original source interpreted for fentanyl only within the stated preparation and endpoint limits.
Not a direct fentanyl combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Hospital patients receiving serotonergic medicines.
Four of4538 co-exposed patients met Hunter criteria on chart review; most did not.
How this applies: Single-center retrospective ascertainment may miss cases; not a 5-HTP, SAMe or tryptophan-specific risk estimate.
Single-center retrospective ascertainment may miss cases; not a 5-HTP, SAMe or tryptophan-specific risk estimate.
Source 5: original transporter experiment
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Laboratory human transporter/receptor models.
Fentanyl did not inhibit SERT/NET in the transporter assay, but interacted with selected serotonin receptors; clinical reports motivated investigation.
How this applies: Original source interpreted for fentanyl only within the stated preparation and endpoint limits.
A transporter-null result does not negate clinical serotonin-syndrome reports or label precautions; not an exact supplement trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact fentanyl article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 90b252c9b8f89768
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.